DHL Supply Chain, a German contract logistics services provider, has launched a new pharma hub in Singapore. This dedicated facility for pharmaceutical logistics represents an investment of $11.37m.
It is part of DHL Group’s broader $568m commitment to enhance its Life Sciences and Healthcare (LSHC) infrastructure across all business units in the Asia Pacific region. It also highlights the firm’s emphasis on the healthcare sector as part of its Strategy 2030. The LSHC sector currently generates $5.68b for DHL’s global revenue, underscoring its importance in the Group’s growth strategy.
Go deeper with GlobalData
The new Pharma Hub, spanning 8,200sqm at 8 Jurong Pier in Singapore, features temperature-controlled areas, creating ideal conditions to store delicate medical supplies. The facility, which adheres to Good Manufacturing Practice (GMP), also includes advanced cold chain infrastructure such as airtight loading docks and specialised anterooms which ensure consistent temperature stability throughout the transportation process.
Javier Bilbao, DHL Supply Chain Asia Pacific CEO, said: “Our investment goes beyond building warehouses or expanding networks. It is about building a foundation across all our business units that enables faster, more reliable delivery of life-saving medicines and healthcare products. In a region where healthcare demand is surging, we enable our customers to focus on innovation and patient care.”
He added, “At the same time, we handle the complexities of supply chain management across all logistics touchpoints – from storage, order fulfillment, and distribution to global shipping and last-mile delivery. This is how we deliver real value: by turning challenges into opportunities and ensuring that every link in the healthcare supply chain works seamlessly.”
The Pharma Hub is situated near Tuas Bio-Medical Park, aiming to provide convenient access to Changi Airport and Tuas Mega Port to enhance distribution capabilities for pharmaceutical partners both regionally and globally.
DHL Group has announced a global investment of $2.27b by 2030 to enhance integrated healthcare solutions. Additionally, it has recently acquired CRYOPDP, a specialty courier that provides end-to-end temperature-controlled solutions and white-glove services tailored for the LSHC industry.
